Business Wire Feed

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

November 21st, 2025|

Represents the first PD-1 inhibitor plus ADC regimens for this patient populationRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration more...

Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025

November 21st, 2025|

Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in multiple patients treated with FOG-001CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines, a clinical-stage more...

AHF Celebrates Legacy of LGBTQ+ Pioneer Morris Kight

November 20th, 2025|

Gay and civil rights icon to be honored and his ashes inurned 22 years after his death at 83 Saturday, November 22, 2025, 1:30 p.m., Hollywood Forever Cemetery – AHF Reception to followLOS ANGELES--(BUSINESS WIRE)--AIDS more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.